
Opinion|Videos|December 22, 2023
Monitoring Patients on Treatment for MF
Author(s)Aaron T. Gerds, MD, MS
Aaron Gerds, MD, MS, explains that myelofibrosis patients on JAK inhibitors need regular monitoring of blood counts, liver enzymes, and cardiac events to check for reactivation.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Gedatolisib Improves PFS in HR+/HER2-/PIK3CA-WT Advanced Breast Cancer
2
Nadunolimab Misses Efficacy Mark in TNBC, Despite Strong OS
3
FDA Approves Niraparib/Abiraterone Combo for BRCA2-Mutated mCSPC
4
Real-World Pola-R-CHP vs R-CHOP Effectiveness in Older DLBCL Patients
5








































